QuidelOrtho Corp (QDEL): EBITDA
-$477.20M
Year ended 2025-12-28
-$370.50M
Trailing 12 months to 2026-06-28
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-28 | -$477.20M | n/m | 2026-02-19, From 2024-12-30 |
| 2024-12-29 | -$1.51B | n/m | 2026-02-19, From 2024-01-01 |
| 2023-12-31 | $596.30M | -47.1% | 2026-02-19, From 2023-01-02 |
| 2023-01-01, Fiscal 2022 | $1.13B | +17.6% | 2025-02-27, From 2022-01-03 |
| 2022-01-02, Fiscal 2021 | $958.70M | -13.6% | 2024-08-01, From 2021-01-04 |
| 2021-01-03, Fiscal 2020 | $1.11B | n/a | 2023-02-23, From 2019-12-30 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| QuidelOrtho Corp (QDEL) | 2025-12-28 | -$477.20M | n/m |
| Idexx Laboratories Inc (IDXX) | 2025-12-31 | $1.51B | +19.6% |
| Lantheus Holdings, Inc. (LNTH) | 2025-12-31 | $380.93M | -27.0% |
| Neogen Corp (NEOG) | 2026-05-31 | $94.70M | n/m |
| Myriad Genetics Inc (MYGN) | 2025-12-31 | -$333.50M | n/m |
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | -$431.22M | n/m |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | -$10.63M | n/m |
| Immucell Corp (ICCC) | 2025-12-31 | $4.43M | +306.8% |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | -$7.80M | n/m |
Compare QDEL, IDXX, LNTH, NEOG side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗